Biosplice Therapeutics Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
120
- Latest Deal Type
-
2ndary - Private
- Financing Rounds
-
11
Biosplice Therapeutics General Information
Description
Operator of a tissue-level therapeutic drugs company focused on osteoarthritis and oncology. The company's platform discovers new targets and biological processes, allowing them to develop small molecule drugs that potentially address numerous degenerative conditions, thereby discovering new curative therapies for certain diseases.
Contact Information
Website
www.biosplice.comCorporate Office
- 9360 Towne Centre Drive
- San Diego, CA 92121
- United States
Corporate Office
- 9360 Towne Centre Drive
- San Diego, CA 92121
- United States
Biosplice Therapeutics Timeline
Biosplice Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biosplice Therapeutics Comparisons
Industry
Financing
Details
Biosplice Therapeutics Competitors (47)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Concert Pharmaceuticals | Corporate Backed or Acquired | Lexington, MA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Scynexis | Formerly VC-backed | Jersey City, NJ | ||||
| VDM Biochemicals | Private Debt Financed | Lake Forest, CA |
Biosplice Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Biosplice Therapeutics Patents
Biosplice Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240199649-A1 | 4-aminopyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof | Pending | 03-Nov-2022 | ||
| US-20240002391-A1 | 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof | Pending | 23-Jun-2022 | ||
| US-20230167133-A1 | 7h-pyrrolo[2,3-d]pyrimidines and preparation and uses thereof | Pending | 12-Oct-2021 | ||
| US-20230192686-A1 | 1h-pyrrolo[2,3-b]pyridines and preparation and uses thereof | Pending | 12-Oct-2021 | ||
| US-20230312605-A1 | Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof | Pending | 12-Oct-2021 | C07D487/04 |
Biosplice Therapeutics Executive Team (16)
| Name | Title | Board Seat |
|---|---|---|
| Cevdet Samikoglu | Chief Executive Officer & Board Member | |
| Erich Horsley | Chief Financial Officer & Chief Business Officer | |
| Scott Bulcao | Chief Legal Officer | |
| Osman Kibar Ph.D | Co-Founder & Executive Chairman | |
| Jeymi Tambiah MD | Senior Vice President of Clinical Development and External Innovation |
Biosplice Therapeutics Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Eventide Asset Management | Board Member | ||
| Biosplice Therapeutics | Chief Executive Officer & Board Member | ||
| SymBiosis Capital Management | Board Observer | ||
| Self | Board Member | ||
| Vickers Venture Partners | Board Member |
Biosplice Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Biosplice Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Biosplice Therapeutics FAQs
-
When was Biosplice Therapeutics founded?
Biosplice Therapeutics was founded in 2008.
-
Who is the founder of Biosplice Therapeutics?
Dennis Carson, Richard Schwab, Osman Kibar Ph.D, and John Hood Ph.D are the founders of Biosplice Therapeutics.
-
Who is the CEO of Biosplice Therapeutics?
Cevdet Samikoglu is the CEO of Biosplice Therapeutics.
-
Where is Biosplice Therapeutics headquartered?
Biosplice Therapeutics is headquartered in San Diego, CA.
-
What is the size of Biosplice Therapeutics?
Biosplice Therapeutics has 120 total employees.
-
What industry is Biosplice Therapeutics in?
Biosplice Therapeutics’s primary industry is Drug Discovery.
-
Is Biosplice Therapeutics a private or public company?
Biosplice Therapeutics is a Private company.
-
What is Biosplice Therapeutics’s current revenue?
The current revenue for Biosplice Therapeutics is .
-
How much funding has Biosplice Therapeutics raised over time?
Biosplice Therapeutics has raised $884M.
-
Who are Biosplice Therapeutics’s investors?
aMoon Fund, Eventide Asset Management, Fortuna Holdings, Plutus Investment Group, and Sands Capital are 5 of 10 investors who have invested in Biosplice Therapeutics.
-
Who are Biosplice Therapeutics’s competitors?
NGM Biopharmaceuticals, Concert Pharmaceuticals, Inovio Pharmaceuticals, Scynexis, and VDM Biochemicals are some of the 47 competitors of Biosplice Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
